Objective  To investigate the influence of intravenous thrombolysis with mouse nerve growth factor for injection and recombinant tissue-type plasminogen activator (rt-PA) on neurological function and serum nerve growth factor (NGF), myelin basic protein (MBP) in patients with acute cerebral infarction (ACI).

  Methods  A total of 98 ACI patients were selected and randomly divided into study group (n=49) and control group (n=49). Both groups were treated with conventional symptomatic treatment after hospital admission. On this basis, the control group was treated with rt-PA by intravenous thrombolysis, while the study group was treated with intravenous thrombolysis with mouse nerve growth factor for injection and rt-PA. The therapeutic effect, NIHSS score and quality of life (SF-36) of the two groups were compared before and after treatment. The serum levels of NGF, MBP and brain-derived neurotrophic factor (BNDF) of the two groups were compared before and after treatment.

  Results  The total effective rate of the study group was 95.92%, which was significantly higher than 81.63% of the control group (P < 0.05). After treatment, the NIHSS score and serum MBP level of the study group were significantly lower than those of the control group, and the levels of NGF and BNDF were significantly higher than those of the control group (P < 0.05). One month after treatment, the scores of vitality, mental health, social function and overall health in the study group were significantly higher than those in the control group (P < 0.05).

  Conclusion  Application of intravenous thrombolysis with mouse nerve growth factor for injection and rt-PA can significantly improve the therapeutic effect, neurological function and quality of life in patients with ACI.